Sophia Genetics has announced that Marylin Mermod Schule, previously a Deputy Director at Benjamin de Rothschild Bank, has joined the company’s management team as CFO. The company has also announced the appointment of new talent in its business development functions, with market experts joining from Roche and Cartagenia.
Marylin Mermod Schule brings with her a wealth of experience. She joined Benjamin de Rothschild in 2006 and held several key roles in corporate finance and private equity, including the co-development of a new private equity division. She also brings a strong ‘Big 4’ accountancy background to Sophia Genetics, having specialised in external audit, transaction support and due diligence in the tech and health sectors.
“It is a testament to the strength of Sophia Genetics that we have been able to attract such experienced and knowledgeable professionals to join our team.” said Jurgi Camblong, CEO and co-founder of Sophia Genetics. “Marylin’s appointment will help us achieve our corporate objectives in a dynamic marketplace, allowing us to take advance of the numerous exciting opportunities that continue to arise. Furthermore, with our additional business development experts, I expect to see a significant uptick in Sophia’s customer acquisition rate.”
As CFO, Marylin will support the continued success of the company, improving operations across different business units, providing strategic insight to maximize growth and navigating private and public financing opportunities. She will report in to Jurgi Camblong, CEO and co-founder.
Sophia Genetics has also appointed two market experts, joining from Roche Diagnostics and Cartagenia. They will support Sophia’s business development and partnership opportunities. Welcoming the new joiners, Jurgi Camblong said: “Sophia’s rapid growth has been made possible by the expertise and passion of our talented team, which will be enhanced by our most recent hires. It is great to welcome new joiners from renowned companies – especially as, through their knowledge of the market, they have chosen to join Sophia and believe that what we provide constitutes best in class technology in the field.”
The new hires join Sophia Genetics as the company signs deals in new markets, including Spain, Turkey, Israel and Poland. Sophia is now working with 60 Hospitals and private labs, and is on track to meet its end of year strategic objective of delivering services to 100 institutional clients.
Please login or sign up to comment.
Commenting guidelines